

# FY2023 1st Half Investor Briefing

#### **CREATIVE CONNECTIVITY**

—Challenge, Creativity, Solutions

SMK Corporation (6798) November 9, 2023


# FY2023 2Q Outline of Financial Statement

Executive Vice President and CFO

KOHEI OHGAKI




## <Consolidated> 2Q Financial Results





## <Consolidated> 2Q Financial Results (by Quarter)





Upper row: Percentage to net sales

Lower row: Increase (decrease)


ratio to FY2022

#### Forecast of consolidated operating results for FY 2023 (Full-year)

Disclosed on	Net Sales		Operating Profit		Ordinary Profit		Net Profit	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Apr. 28, 2023	55,000	100.0 0.3	1,100	2.0 △2.5	1,600	2.9 △36.1	1,100	2.0 △17.6
July 26, 2023	51,000	100.0 △7.0	700	1.4 △38.0	1,100	2.2 △56.1	800	1.6 △40.1
Oct. 25, 2023 New	50,000	100.0 △8.8	100	0.2 △91.1	1,100	2.2 △56.1	800	1.6 △40.1



## <Consolidated> Operating Expenses




Unit: Million yen

Amount paid to subcontractors

- Improved by 2.5%
   in ratio of material costs &
   amount paid to subcontractors
   49.8% → 47.3%
- Raised by 5.6% in ratio of labor costs & expenses  $42.8 \% \rightarrow 48.4\%$




## <Consolidated> Changes in Operating Profit vs. previous corresponding period






## <Consolidated> Changes in Operating Profit vs. initial forecast






## <Consolidated> Non-operating Profit and Loss





## <Consolidated> Extraordinary Profit and Loss





## <Consolidated> Segment Information

FY2023 4-9 Unit: Million yen

		Reporting				
	CS Division	SCI Division	R&D Center	Total	Others*	TOTAL
Net Sales	10,349	12,512	205	23,067	7	23,075
Operating Profit/Loss (△)	526	△608	△91	△173	△3	△177


#### FY2022 4-9

Reporting Segment						
	CS Division	SCI Division	R&D Center	Total	Others*	TOTAL
Net Sales	10,786	16,694	155	27,636	2	27,638
Operating Profit/Loss (△)	644	203	△96	752	0	752

\*Other components business



## <Consolidated> Financial Performance Trend (Full-year)





Unit: Million yen

	Mar. 2023	Sept. 2023	Differential
	(A)	(B)	(B-A)
Assets	56,365	59,140	2,775
Cash and cash equivalents	8,969	9,931	961
Accounts receivable	13,176	13,311	134
Inventories	10,073	10,990	917
Fixed assets	23,113	23,812	699
Liabilities	24,090	25,825	1,735
Accounts payable and accrued expenses	6,652	6,927	274
Interest-bearing debt	12,817	13,830	1,012
Net assets	32,274	33,314	1,040
Common stock	7,996	7,996	_
Capital adequacy ratio	57.3%	56.3%	△1.0%



Unit: Million yen

	FY2022 4-9	FY2023 4-9
Cash flow from operating activities	1,816	2,062
Working capital	△1,985	75
Profit before taxes	3,328	1,264
Depreciation	1,393	1,254
Others	△920	△532
Cash flow from investing activities	△887	△977
Free cash flow	929	1,084
Cash flow from financing activities	631	217
Increase/decrease in interest-bearing debt	1,068	874
Increase/decrease in treasury stock	$\triangle 1$	$\triangle 1$
Dividends paid	△436	△655
Initial balance	8,505	8,915
Final balance	9,736	9,859



	At second quarter end	At fiscal year end	Annual
FY2022 Result	0.00 yen	100.00 yen	100.00 yen
FY2023 Result	<u>50.00 yen</u>		
FY2023 Forecast		<u>50.00 yen</u>	<u>100.00 yen</u>




## FY2023 Prospect

President, CEO and COO

YASUMITSU IKEDA




## Net Sales by Product Div. (FY2022-FY2023)






## Operating Profit by Product Div. (FY2022-FY2023)





## Reference: Net Sales by Market (FY2021-FY2023)





1. Generate sales and profit through enhanced transnational activities.

Develop a new strategy to achieve sustainable growth.

3. Promote ESG management.



### **■** Enhancement of Hitachi Works (Showa Denshi)

- <Objectives>
- ✓ Establishment of production system for new products.
- ✓ Enhancement of domestic production capabilities.
  - ⇒ Production Capacity of SCI products at Hitachi Works: 200%





- ✓ Enhanced participation in public exhibitions (FY2022: 13  $\Rightarrow$  FY2023: 15)
- ✓ Press release on new healthcare business (November 9<sup>th</sup>)

	Exhibition	Date	Venue			
In-house 1 show	SMK Advanced Development Technology Show 2023	Nov. 8-10	Head Office Annex			
	Automotive Engineering Exposition 2023	May 24-26	PACIFICO Yokohama			
	Transport Logistics DX EXPO 2023	May 24-26	Tokyo Big Sight			
Japan 9 shows	Smart Sensing 2023	May 31-June 2	Tokyo Big Sight			
3 3110 773	Pharmacy Solutions Expo 2023	Oct. 11-13	MAKUHARI MESSE			
	Upcoming: [November] Microwave Exhibition [January] Maas EXPO 2024, Wearable EXPO 2024, Factory Innovation Week 2024 [March] Care Technology Expo '24					
	Electronica China 2023	July 11-13	Shanghai, China			
	Thailand Medical Fair	Sept. 13-15	Bangkok, Thailand			
Others 5 shows	Indonesia Hospital Expo 2023	Oct. 18-21	Jakarta, Indonesia			
	3rd NAA B2B Meeting 2023	Nov. 29-30	Aguascalientes, Mexico			
	CES 2024	Jan. 9–12	Nevada, U.S.A.			



Pharmacy Solutions Expo 2023



Thailand Medical Fair



Indonesia Hospital Expo 2023



#### 1. Integrated Report

Published/will be published on the SMK website on October 30th (Japanese) on November 30th (English)

https://www.smk.co.jp/company/ir/integrated report/





by production value

#### 2. Aiming for Carbon Neutrality

- **■** Long-term target: FY2045 Achieve carbon neutrality
- Medium-term target: FY2030 Reduce CO₂ emissions per unit of production value\*

  by 40% compared to FY2020 \*CO₂ emissions divided\*

  \*CO₂ emissions divided\*

<Scope1, 2>

2020 2030 2045 100 60 0

Results (vs. FY2020): FY2021 15% down FY2022 33% down

#### <Scope3>

Started disclosing Scope 3 emissions from FY2022 results (on the ESG DATA page of the SMK website).

#### <Installation of polar power generation systems>

- Japan Toyama and Hitachi Works: operation started
- Overseas Philippines and Malaysia factories: operation started

Mexico factory: scheduled to start operation in January 2024



All information in this material concerning the forecast of business achievements, projections of general business conditions and our business strategies is dependent on our conclusion made to a normally foreseeable extent applying information reasonably accessible to us at the time of preparation of this material.

However, the reality is that it contains risks and uncertainties which may cause result to materially differ from business projections, stated or implied, due to situations which are unforeseeable under normal conditions, or of results which are beyond a reasonably foreseeable outcome at that time.

Despite our active efforts to disclose information which is considered to be important to investors of our company, total dependence on the business projections in this material, stated or implied, must be refrained from when decisions of any kind are made regarding our company.



<sup>\*</sup> Products and company names listed in this material are the registered trademarks or trademarks of their respective holders.